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1. Introduction 
Abdominal aortic aneurysms (AAA) are permanent, irreversible, localised dilatations of 
they aorta. Usually, they develop as a result of a progressive localised weakness within the 
vessel wall. They typically occur below the level of the renal arteries and have a high 
propensity for rupture. In fact, ruptured AAAs account for approximately 8,000 and 15,000 
deaths in the United Kingdom (UK) and United States of America (USA) respectively on an 
annual basis (Sakalihasan et al. 2005, Thompson 2003, Vorp and Vande Geest 2005). Risk 
factors for their development include male gender, age >65 and a history of smoking. Other 
associated risk factors are connective tissue disorders that typically have a genetic 
predisposition, syphilitic infections and cystic medial necrosis. 
Currently, there are two surgical treatments for AAA; the traditional open repair and a 
minimally invasive procedure known as endovascular aneurysm repair (EVAR) (Kamineni 
and Heuser 2004, Parodi et al. 1991, Sakalihasan et al. 2005). The endovascular technique has 
been widely applied in clinical practice, however important limitations persist (Egelhoff et 
al. 1999, Kamineni and Heuser 2004, Parodi et al. 1991). Among these limitations are device 
migration, endoleaks, and thrombotic occlusion. It has been suggested that tissue-
engineered xenografts may play a role for preventing these complications in EVAR. In the 
present chapter we discuss limitations of stent-grafts deployed in the EVAR procedure. We 
place particular emphasis on tissue-engineered extracellular matrices (ECMs) as adjuvant 
scaffolds for optimisation of the EVAR procedure. 
2. Aetiology of aneurysms 
The arterial wall is primarily composed of 3 layers (or tunicae) that surround the luminal 
cavity as illustrated in Fig. 1. The inner layer (or tunica intima) consists of a monolayer of 
endothelial cells. A thin membrane known as the elastica interna separates the tunica intima 
from the tunica media and the tunica media itself consists of concentric layers of smooth 
muscle cells interwoven between networks of connective tissue.  The tunica media is 
separated from the outer tunica adventitia by the elastica externa and adventitial 
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constituents include collagen and interspersed fibroblasts. Elastin is the predominant tissue 
within the aorta and it functions as the principal load bearing element of the aortic wall. 
During aneurysm formation degradation of elastin occurs along the walls of the aorta 
(Raghavan et al. 2005). It is widely believed that degradation of elastin may promote an 
inflammatory response within the wall leading to weakened tissue, abnormal remodelling 
responses and subsequent AAA development. 
 
 
Fig. 1. Histological structure of arterial wall 
Currently, aneurysms are classified relative to their shape and location. Fusiform aneurysms 
are the most common and they typically occur due to a circumferential weakness along an 
extended portion of the aorta with the weakened portion appearing as a symmetrical bulge. 
In contrast saccular aneurysms frequently form on one side of the aorta and are 
asymmetrical in their nature. Finally, pseudoaneurysms usually occur as a result of trauma 
to the aortic wall that causes all 3 layers of the vessel to separate. 
3. Surgical treatment options for AAA 
3.1 Open repair 
Currently there are two vascular procedures available for the treatment of AAA; an open 
procedure and minimally invasive surgery. Open surgery involves a midline incision to gain 
access to the aneurysmal site. Intraoperatively, the aorta and iliac arteries are exposed and 
 
 
Fig. 2. Open repair of abdominal aortic aneurysm (AAA) 
(http://www.musc.edu/radiology/interventional/index.htm) 
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cross-clamped prior to incising the wall of the AAA. Intraluminal thrombi are removed and 
a synthetic graft is sutured in situ before the aneurysm is closed over the graft as illustrated 
in Fig. 2. Complications associated with the open method include infection, increased 
inpatient stay and a predisposition to acute renal failure. 
3.2 Minimally invasive approaches 
The minimally invasive approach involves the use of a stent graft device as illustrated in Fig 
3 and this method is referred to as ‘EndoVascular Aneurysm Repair (EVAR)’. Importantly, 
EVAR is associated with a significant decrease in mortality and reduced duration of 
inpatient stay when compared to open repair; however EVAR has additional procedural 
risks.  
 
 
Fig. 3. Endovascular aneurysmal (EVAR) repair of AAA 
(http://www.musc.edu/radiology/interventional/index.htm) 
3.2.1 Complications associated with EVAR 
Intraoperative complicatons include vascular injury during initial catheterisation and stent 
deployment and postoperative complications associated with EVAR include persistent 
blood flow outside the graft that can result in increased pressure on the aneurysmal sac and 
a subsequent endoleak. To date, endoleaks have been classified into 5 different subtypes and 
types 1-5 are illustrated in table. 1 
 
Endoleak Type Characteristics 
1 
Occurs at proximal or distal end of the stent-graft where it attaches to 
vessel wall 
2 Precipitated by collateral flow from mesenteric or lumbar arteries 
3 
Tear in graft fabric and blood leaks between modular components of stent 
graft 
4 Leak occurs through pores within the graft’s fabric 
5 
Occurs as a result of ‘intra-sac’ pressurisation and is commonly referred to 
as endotension 
Table 1. Endoleaks type 1-5 and their associated clinical features (Greenhalgh and Powell 
2008) 
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Typically, endoleaks that are classified as type 3 or type 4 resolve spontaneously; however 
endoleaks classified as type 1 or type 2 often require surgical intervention (Greenhalgh and 
Powell 2008). Treatment options for type 5 remain controversial as surgeons remain divided 
on advocating immediate surgical repair versus a more conservative surveillance approach 
(Mennander et al. 2005, Veith et al. 2002). 
Migration of the stent-graft following the EVAR procedure is another complication 
associated with considerable postoperative morbidity. Clinically, migration can be defined 
as ≥5mm of distal movement of the stent-graft from its attachment site.  Usually migration 
can be caused by inadequate attachment of the graft to the proximal neck of the aneurysm or 
by morphological changes within the neck of the vessel.  Postoperative complications include a 
widening of the aneurysm that may result in decreased radial force exerted by the proximal 
portion of the stent in vivo.  Radial force is an important fixation method in stent-grafts without 
hooks or barbs and widening of the neck inevitably predisposes these devices to migration. 
Less frequent complications include stenosis or occlusion of the graft or distal vessels. 
On account of these complications only 5 stent-grafts with FDA approval are currently 
available.  These are the AneuRx® and Talent® from Medtronic, the Zenith® from Cook, the 
Gore Excluder® and the Endologix Powerlink® (Endovascular Today, 2009).  Their success 
is also limited by a high incidence of endoleaks and stent migration as illustrated in Table 2. 
Typically, the majority of stent migration failures occur after one year. A reliable method 
that prevents these complications from occurring is an attractive option.  
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Reference 
AneuRx 
Modular 
external 
Nitinol 
external 
Dacron
Nitinol 
skeleton 
No Yes Yes 
(Zarins et 
al. 2001) 
Talent 
Modular 
self-
expanding 
internal 
Nitinol Dacron
Multi 
nitinol 
stents 
(Bare) 
No Yes Yes 
(Criado et 
al. 2003) 
Zenith Modular 
Stainless 
steel 
Dacron Z-stents Yes Yes Yes 
(Greenberg 
2003) 
Gore 
Excluder 
Unitary 
external 
tube type 
and 
internal 
Nitinol 
Teflon 
ePTFE 
Spiral 
shape 
No Yes Yes 
(Bush et al. 
2001) 
Endologix 
PowerLink 
Unitary 
Body 
internal 
stent type 
Cobalt-
Chromium 
Alloy 
ePTFE 
Single 
wire Z-
shaped  
No Yes Yes 
(Wang et 
al. 2008) 
Table 2. Stent graft devices for EVAR: Their structural properties and associated 
complications 
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3.3 Possible method for improvement of EVAR  
Previously, investigations for improving the stent-graft design have predominantly 
focussed on the mechanical aspects of the stent. In general, most of these investigations have 
failed and a reliable solution remains elusive. Recent investigations (Brown et al. 2006, 
Schoder et al., 2004, Niyyati et al. 2005, Yavuz et al. 2006) suggest that tissue-engineered 
extracellular matrix (ECM) scaffolds derived from xenogenic sources may have the potential 
to overcome limitations that are associated with traditional mechanical solutions.  
4. Tissue-engineered Extracellular matrix (ECM) scaffolds 
Extracellular matrices (ECMs) are biological scaffolds usually derived from xenogenic 
sources. They are acellular in nature and induce a host derived tissue-remodelling response 
after implantation while undergoing simultaneous degradation processes (Davis et al., 
2010). Therefore, they may provide an attractive alternative as suitable biomaterials for 
improving EVAR treatment of AAA. Urinary bladder matrix (UBM) and small intestine 
submucosa (SIS) are two common ECM scaffolds of porcine origin that have had good 
clinical outcomes after surgical implantation across numerous subspecialties. These 
biomaterials are prepared via numerous physical, chemical and enzymatic processes. 
 
Author (Year) Application 
Animal 
Model 
Result 
S.F. Badylak 
(1989) 
Large diameter 
vascular graft 
Canine 
No thrombus formation and no intimal 
hyperplasia after 44 weeks. No 
endothelialisation of the scaffold and greater 
stiffness within the scaffold compared to 
artery 
D.J. Schultz 
(2002) 
Reparation of 
enterocutaneous 
fistula 
Human No data available 
S.G. de la 
Fuente (2002) 
Gastric reparation Rat Regeneration of gastric mucosa after 3 weeks 
M. Chen 
(2001) 
Small intestine Canine 
Tubular failure secondary to obstruction and 
leakage 
M.A. Cobb 
(1999) 
Dura mater 
substitute 
Canine Complete resorption after 60 days 
M. Rosen 
(2002) 
Regeneration of 
biliary system 
Canine 
Infiltration with fibroblasts after 2 weeks. 
Biliary epithelium replaced with native 
collagen after 3 months. 
S.F. Badylak 
(2001) 
Body wall repair Canine 
Preoperative tensile strength achieved after 
24 months 
T.G. Smith 
(2002) 
Reparation of 
ureteral defect 
Porcine 
SIS graft replaced with urothelium and 
smooth muscle after 9 weeks 
B.P. Kropp 
(1995) 
Urinary bladder 
regeneration 
Rat 
Urothelium, lamina propria and smooth 
muscle replaced within 3 weeks 
Table 3. Multisystemic applications for SIS and associated remodelling duration after in vivo 
implantation 
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Extensive experimental evaluation of SIS and UBM materials has been undertaken; 
examining sterilisation effects, cell interactions, cell growth effects, gene expression, 
mechanical properties, processing effects, suture retention effects and repeatability issues 
associated with their clinical applications (Ahn et al. 2007, Cimini et al. 2005, Freytes et al. 
2005, Freytes et al. 2008, Gilbert et al. 2006, Hodde et al. 2002, Roeder et al. 1999, Sellaro et al. 
2007, Teebken et al. 2000). These characterisation methods have led to a greater 
understanding of an ECM’s biological, structural and mechanical properties. Clinical 
applications of ECM scaffolds are described in Table 3. Influences such as stent interaction, 
compliance differences, aortic endothelial cell interactions and flow effects, have not been 
fully characterised on ECMs using in vitro or in vivo experimental approaches.  
Although UBM has been utilised to a lesser extent compared to SIS, it has been successfully 
applied for the treatment of dysplastic oesophygeal tissue with excellent patency rates 
during the follow up period (Badylak et al., 2005). In addition, UBM has been applied for 
effectively treating strictures of the trachea with no evidence of stenosis or tracheomalacia 
during the follow up period (Gilbert et al. 2008). Finally, UBM has also been effectively 
applied for reparation of the thoracic wall in a canine model (Gilbert et al. 2007).  
4.1 Constituents and preparation of ECMs  
The major constituents found within mammalian ECMs are collagen, glycoproteins, 
glycosaminoglycans (GAGs) and growth factors as illustrated in Table 4. These constituents 
provide structural, functional, adhesive and stimulatory functions to their surrounding cells 
enabling them to survive and proliferate (Badylak et al. 2009, Baldwin 1996, Laurie et al. 
1989). Naturally, the transition phase of an ECM scaffold from intact mammalian tissue to 
viable donor xenograft material requires several processing steps. Initially, the native tissue 
is manually separated from unwanted tissue structures. Tissue decellularisation is achieved 
through a combination of sonication, agitation, freezing and thawing processes (Badylak et 
al. 2009). These treatments disrupt the cell membrane and facilitate the removal of 
intracellular remnants. During the decellularisation process it is of paramount importance to 
preserve as many mechanical and biological properties of the donor ECM as possible. 
Disruption of collagen architecture can decrease the mechanical strength of the scaffold,  
removal of GAGs adversely affect its viscoelastic behaviour and the absence of growth 
factors will decrease the scaffold’s bioinductive properties (Lovekamp et al. 2006). After the 
xenograft is decellularised it is then sterilised by exposure to irradiation or ethylene oxide 
(Rosario et al. 2008).  
To date, porcine SIS and porcine UBM have been strongly favoured as potential donor 
scaffolds for many different surgical subspecialties. Their harvesting sites differ; however 
both have had a considerable degree of success when applied clinically. SIS is harvested 
from the small intestine and UBM originates from the urinary bladder. Their collagen 
components also differ to a small extent after decellularisation and sterilisation. The 
decellularised SIS scaffold is primarily composed of collagen type 1 (Badylak et al. 2009) 
with smaller amounts of collagen types 3, 4, 5, 6  also present (Badylak SF 1995). In contrast, 
UBM is rich in collagen types 3, 4 and 7. UBM possess an intact basement membrane which 
has many characteristics that favour its application to the vasculature. Importantly, a 
basement membrane may support the growth and differentiation of a confluent endothelial 
cell layer on the luminal surface of the scaffold. Different characteristics of SIS and UBM are 
compared in Table 5.  
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Constituents Features 
Collagen 
• Most abundant protein within ECMs 
• More than 20 different types have been identified 
• Provides distinct mechanical and physical properties to the 
ECM 
Laminin 
• Large adhesion glycoprotein 
• Involved in cell and tissue differentiation  
• Promotes tissue development and angiogenesis 
Fibronectin 
• Extracellular glycoprotein 
• Promotes host biocompatibility 
• Induces cell adhesion by binding to membrane-spanning 
receptor proteins known as integrins  
Glycosaminoglycans
• Mucopolysaccharides 
• Bind covalently to a protein core to form a proteoglycan 
molecule 
• Act as a reservoir when cells stop growth factor production 
• Enables ECMs to store growth factors that may be used during 
tissue regeneration 
Growth Factors 
• Present in small quantities within ECMs 
• Naturally occurring substances capable of stimulating cellular 
growth, proliferation and differentiation 
Table 4. Constituents of ECM scaffolds and their associated biological features 
 
Extracellular Matrix Characteristics 
Small Intestinal Submucosa (SIS)
• Derived from porcine jejunum 
• Primarily composed of the submucosal layer and 
the stratum compactum of the tunica mucosa 
• Mainly consists of type 1 collagen 
Urinary Bladder Matrix (UBM) 
• Derived from the porcine urinary bladder 
• Possesses an intact basement membrane consisting 
of collagen types 4 and 7 
Table 5. Differentiating the characteristics of SIS from UBM 
4.2 Immunogenic response after implantation 
Theoretically, an implanted ECM should not elicit an immediate or delayed immune 
response due to its acellular and avascular nature (Allman et al. 2001, Ho et al. 2004, 
Sandusky et al. 1992). However, we know that elimination of all nuclear materials and cell 
membrane products is almost impossible despite extensive measures taken during the 
decellularisation process. Therefore, it is expected that the recipient should mount an 
immune response against the graft’s cell remnants and arguably, against the intact 
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xenogenic proteins. This hypothesis has been extensively studied by assessing the host’s 
cell-mediated T-helper 1 (rejection) and T-helper 2 (accommodation) immune responses to 
implanted xenografts (Strom et al. 1996, Zhai et al. 1999) . 
Results from preliminary studies on mice are favourable, as the implanted SIS scaffold elicits 
an immune lymphocytic response that is predominately Th2-like (Allman et al. 2001). The 
Th-2 pathway stimulates the production of interleukins IL-4, IL-5, IL-6 and IL- 10. These 
interleukins promote graft acceptance and prevent the activation of neighbouring 
inflammatory macrophages (Bach et al. 1997, Chen and Field 1995) . Activation of the Th2 
pathway also promotes effective tissue remodelling, structural repair and functional 
recovery of the injured tissue after graft acceptance (Piterina AV 2009). Undoubtedly, 
activation of this humoral response is encouraging as activation of the alternate lymphocytic 
pathway (i.e. Th1) produces an acute inflammatory reaction. Cytokines such as IL-2, 
interferon (IFN) gamma and tumour necrosis factor (TNF) beta activate neighbouring 
macrophages and stimulate the differentiation of CD 8+ cells to a cytotoxic phenotype. This 
host derived inflammatory response ultimately leads to xenogenic graft rejection (Abbas et 
al. 1996, Matsumiya et al. 1994).  
The terminal alpha 1,3 galactose epitope (Gal-epitope) is present in cell membranes of all 
mammals except humans and concerns over the epitope’s inflammatory potential exist 
(Galili 1993, Koren et al. 1994). In humans this epitope (i.e. antigenic determinant) is 
recognised by IgM, IgG and IgA antibodies that mediate hyperacute or delayed graft 
rejection through complement fixation and antibody dependent cell mediated cytotoxicity 
(Good et al. 1992, Koren et al. 1994, Schussler et al. 2001). The potential for complement 
activation has been investigated with results suggesting that it does not occur when the graft 
is implanted (McPherson et al. 2000). Researchers have attributed the absence of host 
immune responses to the distribution of the epitope within the xenograft and to the minute 
quantities that are present (McPherson et al. 2000). In whole organ transplantation levels of 
the Gal-epitope are expectantly higher and these high levels have been linked to chronic 
graft rejection (Schussler et al. 2001). Currently, methods of eliminating the epitope prior to 
scaffold implantation are under investigation and it has been suggested that treatment of the 
xenogenic scaffold with alpha galactosidase during the decellularisation process is a 
potential solution. Should clinical concerns persist it might also be possible to harvest the 
graft material from transgenic Gal-knockout pigs that are bred specifically for tissue 
engineering purposes. 
The graft’s response to potential host derived pathogenic micro-organisms has also raised 
concerns among vascular surgeons as graft infection is associated with considerably 
morbidity. The xenograft’s response to Gram-positive and Gram-negative bacteria has been 
evaluated and compared to conventional synthetic graft materials (i.e. 
polytetrafluoroethylene) in animal studies (Badylak et al. 2003). Interestingly, xenogenic 
ECM materials were resistant to persistant bacterial infection after deliberate contamination 
at the graft implantation site. This has been attributed to the presence of multiple low-
molecular weight peptides that survive the decellularisation and sterilisation processes 
(Brennan et al. 2006, Sarikaya et al. 2002). These peptides demonstrate bacteriostatic activity 
against micro-organisms and inhibit bacterial proliferation for up to 12 hours after initial 
exposure. Their antimicrobial activity protects the remodelling site from circulating 
pathogens (Brennan et al. 2006). However, their origin and structural homology to natural 
antimicrobial peptides (AMP) and defensins are important aspects that have not been 
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clarified to date. Their spectrum of activity and pathways of incorporation are also poorly 
understood. These factors need to be thoroughly investigated so the extent of their 
antibacterial role can be clearly established. 
4.3 Remodelling and degradation  
Biological growth factors found within SIS and UBM are key contributors to cell growth and 
tissue regeneration (Babensee et al. 2000, Tabata 2004, Tabata 2005). Proteoglycans facilitate 
their survival during matrix decellularisation and sterilisation by functioning as storage 
vessels (Hodde et al. 2005). As the matrix is implanted growth factors are released 
stimulating angiogenesis, host cell infiltration and mitogenesis (Table 6). Matrix degradation 
coincides with this and the degradation process is influenced by host derived enzymatic and 
cellular processes (Badylak 2007). During the degradation process growth factors dissociate 
from their binding proteins and are activated to promote tissue neovascularisation. Matrix 
degradation and growth factor activation continues until the ECM scaffold is completely 
replaced by host cells (Clyne and Edelman 2009). 
 
Growth Factor Function 
Vascular Endothelial Growth 
Factor (VEGF) 
Regulates angiogenesis by controlling blood vessel 
formation and growth 
Platelet Derived Growth 
Factor  (PDGF) 
Deposition of granulation tissue and stimulation of 
angiogenesis 
Bone Morphogenetic Protein    
(BMP) 
Stimulates formation of bone and cartilage 
Keratinocyte Growth Factor       
(KGF) 
Epithelialisation of wounds during healing 
Fibroblast Growth Factor           
(FGF) 
Induces growth of fibroblasts and endothelial cells during 
wound healing 
Transforming Growth Factor     
(TGF-beta) 
Reorganization of matrix molecules to improve dermal 
architecture and reduce scarring 
Table 6. Bioinductive growth factors found within the ECMs and their functions 
Common growth factors that influence tissue remodelling responses include ‘Vascular 
Endothelial Cell Growth Factor’ (VEGF) and ‘basic Fibroblast Growth Factor (bFGF)’ as 
illustrated in Table 6. VEGF has been shown to stimulate angiogenesis, vascular 
permeability and endothelial cell proliferation and migration while bFGF encourages 
wound healing (Ferrara et al. 1992). Other retained growth factors within the ECM include 
keratinocyte growth factor (KGF) which mediates epithelial cell proliferation and 
differentiation (Alpdogan et al. 2006) and platelet-derived growth factor-beta-polypeptide 
(PDGF-BB) which promotes chemotaxis, proliferation, angiogenesis and tissue remodelling. 
It appears that the strong remodelling effect exerted by biological growth factors is 
accentuated by cryptic peptides that are also released from the implanted scaffold during 
the degradation process. These peptides are involved in recruiting circulating bone-marrow 
derived cells that can partake in long-term tissue remodelling processes (S. F. Badylak et al. 
2001, Zantop et al. 2006).  
An ability to be completely degraded while stimulating a native remodelling response over 
a relatively short period of time is perhaps ECM’s most attractive feature (Badylak et al. 
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2000, Davis et al. 2011, Gilbert et al. 2007). These impermanent properties were investigated 
by determining the rates of in vivo graft degradation and excretion in canine models during 
the nineties (Badylak et al. 1998, Kropp et al. 1995, Kropp et al. 1996a, Kropp et al. 1996b, 
Vaught et al. 1996). Studies show that xenogenic ECMs are rapidly degraded and absorbed 
when implanted in the genitourinary tract with up to 90% of the scaffold being replaced by 
host tissue within 28 days (Badylak et al. 1998, Record et al. 2001). Generally, excretion rates 
of all ECMs vary between 28 and 90 days depending on the type of tissue that is being 
remodelled (Allman et al. 2001, Badylak et al. 1998, Record et al. 2001). Naturally, the 
process may be prolonged when multiple layers of xenogenic scaffold are implanted (e.g. 
90-120 days). Shortly after the degradation process the ECM briefly enters the blood stream 
and is excreted via the kidneys through glomerular filtration. This has been shown by 
measuring quantitative studies of   14C- labelled SIS after augmentation cystoplasty in canine 
models (Record et al. 2001). More than 50% of the scaffold was removed from the 
implantation site at 28 days and almost 100% of the scaffold was replaced by 100 days. 
During the follow up period 95% of degradation products were found in the host’s urine 
(Badylak et al. 2000, Record et al. 2001).  
4.4 Mechanical properties  
ECMs’ remodelling capacity is dependent on the preservation of bioinductive growth 
factors during the sterilisation process. Similarly, its mechanical effectiveness is largely 
dependent on preserving intact collagenous arrangements and adhesive glycoproteins 
during this process. This is highlighted by the scaffold’s mechanical response to different 
sterilisation techniques. Studies have shown that the graft’s uniaxial and biaxial mechanical 
properties are significantly reduced after exposure to gamma irradiation, electron beam 
irradiation and ethylene oxide (Freytes et al. 2008) . The reduction in mechanical strength is 
dose-dependent and this emphasises the preparation difficulties encountered between graft 
sterilisation and constituent preservation techniques (Gouk et al. 2008).  
Short-term mechanical limitations are also present during the initial remodelling response 
(Davis et al. 2011). Typically, both SIS and UBM show a decrease in mechanical strength 
after implantation that is caused by a temporal imbalance between  the rate of scaffold 
degradation and the rate of infiltrating host cell deposition (Gilbert et al. 2007). While the 
rapid degradation rate of implanted genitourinary ECMs is often lauded, one must consider 
the temporal mismatch that occurs between xenograft degradation and host-derived matrix 
deposition. One study demonstrated a 30-fold decrease in bladder compliance (in 
comparison to the pre-operative status) after canine urinary bladder was replaced with SIS  
(Kropp et al. 1996b). 
Short-term strength limitations have been addressed by increasing the number of layers 
within the implanted scaffold as a single layer of implanted SIS has proved insufficient for 
most load bearing organs. The graft’s mechanical strength increases by 150% simply by 
increasing the number of layers of SIS layers from 2 to 4 (Freytes et al. 2004). Importantly, 
the imbalance between matrix degradation and deposition is temporary in nature and is 
only relevant until the host’s remodelling capability equates-to or surpasses the ECM’s 
degradation rate. A rapid remodelling response can occur once infiltrating host cells self-
organise and begin producing their own ECM. This results in a time dependent return to 
expected mechanical strength and site-appropriate mechanical behaviour after xenogenic 
implantation (S. Badylak et al. 2001, Badylak et al. 2005, Liang et al. 2006). 
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5. ECMs as potential vascular grafts 
A number of studies have investigated SIS’s potential as a tissue-engineered vascular 
substitute. Initially, Badylak et al. replaced a segment of canine aorta in 1989 with a 
tubularised SIS scaffold (Badylak et al. 1989). Results from this preliminary study 
demonstrated patency of the aorta during the follow up period. Importantly, adverse effects 
such as infection, thrombosis, intimal hyperplasia and hypertension were avoided. 
Histological assessment after follow up revealed organised, dense non-thombogenic 
collagenous connective tissue. However, there was no evidence of endothelial cell growth 
on the luminal surface of the SIS graft after 44 weeks. The authors concluded by suggesting 
that SIS merits further investigation as a large diameter graft for aortic replacement 
purposes. Consequentially, SIS was subsequently investigated as a potential small diameter 
graft in a canine model (Lantz et al., 1990) where the biological scaffold replaced the carotid 
and femoral artery (Lantz et al. 1990). Like Badylak et al., results from this study indicated 
no evidence of endothelial growth on the scaffold’s luminal surface. Luminal and abluminal 
surfaces of the scaffold were comprised of dense organised collagenous tissue, with no 
evidence of infection, propagating thrombus or intimal hyperplasia.   
A more comprehensive study by Sandusky et al. also evaluated SIS as a small calibre 
vascular graft for carotid arteries in canine models in 1992 (Sandusky et al. 1992). A sample 
size of 24 canine models was included in this study over a period of 180 days where gold 
standard saphenous vein grafts were directly compared with SIS scaffolds. Results from this 
study revealed endothelialisation of the SIS scaffold with transmural growth of capillaries 
and infiltrating smooth muscle cells from the host. In addition, no significant differences 
were noted between saphenous vein grafts and SIS scaffolds when intimal thickening was 
compared in this study. In 1995 Hiles et al. assessed the mechanical properties of SIS as a 
potential aortic graft in a canine model (Hiles et al. 1995). Their study demonstrated that 
host tissue completely replaced the SIS scaffold and that the remodelled scaffold had 
appropriate physical and mechanical properties to adequately function in a vascular system. 
However, compliance values from the remodelled SIS construct were three-fold lower than 
compliance values of a normal thoracic aorta (Hiles et al. 1995).  
Another study by Roeder et al. also investigated the compliance, burst pressure and 
remodelling effects of SIS as a small diameter vascular graft (Roeder et al. 2001). Findings 
from their study demonstrated a degree of tissue remodelling with improved compliance at 
the site of the implanted SIS scaffold. The authors concluded by suggesting that mechanical 
properties of the remodelled SIS scaffolds were similar to the vessel of the animal model that 
was replaced. Ovine models have also been utilised to assess SIS’s potential as a small 
diameter vascular graft (Pavcnik et al. 2009). One study, evaluated the implanted SIS 
scaffolds with angiography during their follow up period.  Angiographic assessment of 
implanted SIS scaffold revealed a multitude of complications that included stenosis of the 
anastamotic site, aortic dissections, recurrent aneurysmal formation and diffuse dilatations 
of the implanted scaffold. 
Although SIS has been extensively investigated as a potential vascular replacement scaffold 
it is interesting to note that UBM has never been previously investigated for this purpose. 
Encouragingly, more recent studies have suggested that UBM merits further investigation as 
a potential vascular substitute (Badylak 2005, Brown et al. 2006). After the preparation 
process UBM can be manipulated into many different physiological configurations. Its 
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malleable nature in conjunction with its biocompatibility may provide researchers with an 
alternative ECM scaffold for vascular replacement purposes. 
6. Justification of ECMs in EVAR  
In EVAR failure of the implanted stent most frequently occurs one year after surgical 
implantation as discussed in section 3.2.1. However, ECMs take approximately 3 months to 
induce a constructive tissue remodelling effect (Badylak 2005, Gilbert et al. 2008). Therefore, 
a tissue-engineered ECM is likely to reabsorb within this 12 month timeframe and provide a 
secure seal that could potentially prevent the complication of stent migration. 
6.1 Disadvantages of biodegradable polymers  
The potential for biodegradable polymers as potential vascular replacements in EVAR stent-
grafts has previously been investigated. Poly D, L-lactic–glycolic acid co-polymer (PLGA) 
and Poly ε-caprolactone (PCL) are 2 polymers that have been assessed in vivo and in vitro as 
potential vascular substitutes. In one study the degradation rates of both polymers were 
assessed and compared in vivo and in vitro. Results demonstrated that degradation rates of 
both scaffolds occurred at a more rapid rate in vivo compared to in vitro. Hydrolysis of 
PLGA and PCL polymers were influenced by the concentration of carboxylic acid end-
groups. Therefore, it appears that degradation products of both polymers may serve as 
catalysts for reactions in static conditions, which are likely to accelerate degradation. This 
study suggests that by-products of the initial degradation influence the effect of cell 
infiltration (Sung et al. 2005). Therefore, these initial studies imply that biodegradable 
polymers are unsuitable in the setting of EVAR as they are associated with undesirable by-
products that adversely affect their degradation rate  (Sung et al. 2005).  
6.2 Configurations of ECM stent grafts for EVAR  
SIS has been investigated in a stented environment on the abdominal aorta of ovine models 
where remodelling of the SIS scaffold onto the aortic wall was assessed by Yamada et al. 
(Yamada et al. 2001). In this study the SIS stent graft was manufactured by sandwiching the 
stent between two sheets of SIS as illustrated in Fig. 4. Results demonstrated no evidence of 
stenosis and no evidence of endoleak formation around the implanted stent grafts. 
Histological assessment showed incorporation of the graft into the wall of the aorta with a 
dense neo-intima replacing the SIS scaffold. Endothelialisation occurred in areas where the 
graft was in direct contact with the aortic wall and central portions of the graft were 
partially endothelialised after the 12 week follow up period. A similar study by Noishiki et 
al., 2001 reported comparable results to Yamada et al. with a partial endothelium forming on 
the implanted SIS hybrid stent graft (Noishiki et al. 2001). 
After these promising results the performance of SIS covered endografts (stent devices) 
implanted into ovine femoral arteries was investigated by Nakata et al. in 2003. The study 
compared the performance of the SIS covered endografts to non-covered nitinol stents and 
PTFE covered endografts. In their conclusion the authors suggest that SIS and bare metal 
nitinol stents display similar attachment features to the aortic wall and performed superior 
to a poly-tetra-fluoro-ethylene (PTFE) covered stent also included in the study (Nakata et al. 
2003). It should also be noted that both SIS endografts and bare nitinol stent exhibited 
eccentric intimal hyperplasia with eventual occlusion of the stented vessel during the follow 
www.intechopen.com
Tissue-Engineered Extracellular Matrices (ECMs)  
as Adjuvant Scaffolds for Endovascular Aneurysmal Repair (EVAR) 
 
313 
up period. A study by Schoder et al. also investigated SIS in the setting of EVAR repair 
(Schoder et al. 2004). In this study the SIS scaffold was suspended against the wall of the 
aorta as illustrated in Fig. 5. Results from this study suggest that this deployment method is 
promising for the prevention of type 2 endoleaks. In addition, results also demonstrated 
evidence of a host derived tissue remodelling response during the follow up period. A 
detailed analysis of the remodelling response revealed an established endothelium along the 
distal and proximal regions of the scaffold with poor endothelialisation of its central 
portion.  
 
 
Fig. 4. Sandwiched stent composed of SIS (Yamada et al., 2001) 
 
 
Fig. 5. SIS stent graft deployed inside an AAA (Schoder et al., 2004)  
In 2005 Niyyati et al. assessed the potential for SIS as an intrahepatic protocaval shunt. Only 
one device remained functional in 6 animals after a 14 day experimental time period 
(Niyyati et al. 2005). Intuitively, the authors discouraged SIS in this setting. The configured 
SIS stent device and the implanted SIS stent are illustrated in Fig. 6 A and B. Histological 
assessment of the luminal surface after follow up demonstrated a smooth neointima on the 
surface of the functional stent. 
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Fig. 6. (A) Stent SIS configuration, (B) Gross section through excised graft implantation 
(Niyyati et al. 2005) 
A more recent study investigated the effects of different stent grafts on the portal vein of 
canine models (Ishii et al., 2005). In this study, four different stents were assessed, bare 
metal stent, PTFE covered stent, Dacron covered stent and an SIS covered stent. The study 
concluded that SIS covered stents confer no advantages in comparison to other conventional 
stent grafts. In fact PTFE consistently outperformed the other 3 stents and was 
recommended as the most suitable stent for implantation into the portal vein. In 2006 the 
endothelialisation of an implanted SIS stent graft was compared with Dacron and PTFE in 
an ovine model. In this study the stent grafts were inserted into the thoracoabdominal aorta 
and endothelialisation of the stent graft was assessed during the follow up period (Yavuz et 
al. 2006). Results showed that Dacron exhibited the greatest and most progressive amount of 
endothelialisation. In comparison, SIS demonstrated progressive tissue remodelling and a 
moderate amount of neointimal formation. 
7. Concept solution 
A potential mechanism for improving the performance of the EVAR stent-graft is the 
insertion of a tissue-engineered stabilisation collar at the proximal and distal ends of the 
device as illustrated in Fig. 7.  
A tissue-engineered ‘stent-collar’ may prevent common complications such as endoleaks 
and graft migration. Intuitively, a number of important critical issues need to be addressed 
prior to implementation of this possible solution. Compliance of the scaffold in tubular 
structures and the reduction in the scaffold’s strength caused by interactions with the ‘stent-
graft’ should be investigated. Compliance issues may arise due to fluid flow and elastic 
characteristics of the arterial wall exerted on the tissue-engineered scaffold. Furthermore, 
radial forces exerted by the stent-graft induce stress loadings on the surface of the tissue-
engineered scaffold.   Structural properties of the scaffold also need to be accurately 
characterised. The scaffold’s potential to induce cellular attachment and host derived tissue-
remodelling responses need to be explored. Contact between the tissue-engineered material 
and arterial wall may result in cell infiltration from the host’s endothelium (Fig. 8). To date 
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the majority of these questions remain unanswered and require further research to 
adequately develop ECM scaffolds into AAA endovascular treatment. 
 
 
Fig. 7. Possible solution for optimisation and stabilisation of the stent graft during EVAR. 
(Adapted from http://www.medtronic.com/your-health/abdominal-aortic-
aneurysm/getting-a-device/surgery) 
 
 
Fig. 8. ECM collar interacting with aortic wall to anchor the stent-graft and prevent 
migration of the device 
ECM Located at 
proximal and distal 
portion of the Graft 
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8. Conclusions  
In this chapter we have examined key issues associated with medium-term failure of 
endovascular stents used in the EVAR procedure. Common complications associated with 
EVAR include endoloeaks and migration of the deployed stent. Although tissue-engineered 
xenografts offer an attractive alternative for improving the EVAR procedure, it is notable 
that implantation of ECM scaffolds into stented environments have shown conflicting 
results to date. Encouragingly, the advent of alternative types of biological ECMs, such as 
UBM, has opened up new avenues for researchers with an interest in optimizing the EVAR 
procedure.  Development of a tissue-engineered scaffold that optimizes the performance of 
the stent-graft remains a valuable possibility and exciting option for the future. 
9. Acknowledgements  
This was supported by Enterprise Ireland Commercialisation Funds with a Proof of Concept 
Phase and Technology Development Phase grants, and also by the Irish Research Council 
for Science, Engineering & Technology (IRCSET) - Marie Curie International Mobility 
Fellowship. 
10. References 
Abbas, A. K., Murphy, K. M. and Sher, A. (1996) 'Functional diversity of helper T 
lymphocytes', Nature, 383(6603), 787-93. 
Ahn, H. H., Kim, K. S., Lee, J. H., Lee, M. S., Song, I. B., Cho, M. H., Shin, Y. N., Kim, M. S., 
Khang, G. and Lee, H. B. (2007) 'Porcine small intestinal submucosa sheets as a 
scaffold for human bone marrow stem cells', Int J Biol Macromol, 41(5), 590-6. 
Allman, A. J., McPherson, T. B., Badylak, S. F., Merrill, L. C., Kallakury, B., Sheehan, C., 
Raeder, R. H. and Metzger, D. W. (2001) 'Xenogeneic extracellular matrix grafts 
elicit a TH2-restricted immune response', Transplantation, 71(11), 1631-40. 
Alpdogan, O., Hubbard, V. M., Smith, O. M., Patel, N., Lu, S., Goldberg, G. L., Gray, D. H., 
Feinman, J., Kochman, A. A., Eng, J. M., Suh, D., Muriglan, S. J., Boyd, R. L. and van 
den Brink, M. R. (2006) 'Keratinocyte growth factor (KGF) is required for postnatal 
thymic regeneration', Blood, 107(6), 2453-60. 
Babensee, J. E., McIntire, L. V. and Mikos, A. G. (2000) 'Growth factor delivery for tissue 
engineering', Pharm Res, 17(5), 497-504. 
Bach, F. H., Ferran, C., Hechenleitner, P., Mark, W., Koyamada, N., Miyatake, T., Winkler, 
H., Badrichani, A., Candinas, D. and Hancock, W. W. (1997) 'Accommodation of 
vascularized xenografts: expression of "protective genes" by donor endothelial cells 
in a host Th2 cytokine environment', Nat Med, 3(2), 196-204. 
Badylak, S., Kokini, K., Tullius, B. and Whitson, B. (2001) 'Strength over time of a resorbable 
bioscaffold for body wall repair in a dog model', J Surg Res, 99(2), 282-7. 
Badylak, S., Meurling, S., Chen, M., Spievack, A. and Simmons-Byrd, A. (2000) 'Resorbable 
bioscaffold for esophageal repair in a dog model', J Pediatr Surg, 35(7), 1097-103. 
Badylak, S. F. (2005) 'Regenerative medicine and developmental biology: the role of the 
extracellular matrix', Anat Rec B New Anat, 287(1), 36-41. 
Badylak, S. F. (2007) 'The extracellular matrix as a biologic scaffold material', Biomaterials, 
28(25), 3587-93. 
www.intechopen.com
Tissue-Engineered Extracellular Matrices (ECMs)  
as Adjuvant Scaffolds for Endovascular Aneurysmal Repair (EVAR) 
 
317 
Badylak, S. F., Freytes, D. O. and Gilbert, T. W. (2009) 'Extracellular matrix as a biological 
scaffold material: Structure and function', Acta Biomater, 5(1), 1-13. 
Badylak, S. F., Kropp, B., McPherson, T., Liang, H. and Snyder, P. W. (1998) 'Small 
intestional submucosa: a rapidly resorbed bioscaffold for augmentation cystoplasty 
in a dog model', Tissue Eng, 4(4), 379-87. 
Badylak, S. F., Lantz, G. C., Coffey, A. and Geddes, L. A. (1989) 'Small intestinal submucosa 
as a large diameter vascular graft in the dog', J Surg Res, 47(1), 74-80. 
Badylak, S. F., Park, K., Peppas, N., McCabe, G. and Yoder, M. (2001) 'Marrow-derived cells 
populate scaffolds composed of xenogeneic extracellular matrix', Exp Hematol, 
29(11), 1310-8. 
Badylak, S. F., Vorp, D. A., Spievack, A. R., Simmons-Byrd, A., Hanke, J., Freytes, D. O., 
Thapa, A., Gilbert, T. W. and Nieponice, A. (2005) 'Esophageal reconstruction with 
ECM and muscle tissue in a dog model', J Surg Res, 128(1), 87-97. 
Badylak SF, V. S., Kokini K, et al. (1995) 'The use of xengenic small intestinal submucoas as a 
biomaterial for Achilles tendon repair in a dog model ', J Biomed Mater Res,, 29, 977-85. 
Badylak, S. F., Wu, C. C., Bible, M. and McPherson, E. (2003) 'Host protection against 
deliberate bacterial contamination of an extracellular matrix bioscaffold versus 
Dacron mesh in a dog model of orthopedic soft tissue repair', J Biomed Mater Res B 
Appl Biomater, 67(1), 648-54. 
Baldwin, H. S. (1996) 'Early embryonic vascular development', Cardiovasc Res, 31 Spec No, 
E34-45. 
Brennan, E. P., Reing, J., Chew, D., Myers-Irvin, J. M., Young, E. J. and Badylak, S. F. (2006) 
'Antibacterial activity within degradation products of biological scaffolds 
composed of extracellular matrix', Tissue Eng, 12(10), 2949-55. 
Brown, B., Lindberg, K., Reing, J., Stolz, D. B. and Badylak, S. F. (2006) 'The basement 
membrane component of biologic scaffolds derived from extracellular matrix', 
Tissue Eng, 12(3), 519-26. 
Bush, R. L., Najibi, S., Lin, P. H., Weiss, V. J., MacDonald, M. J., Redd, D. C., Martin, L. G., 
Chaikof, E. L. and Lumsden, A. B. (2001) 'Early experience with the bifurcated 
Excluder endoprosthesis for treatment of the abdominal aortic aneurysm', J Vasc 
Surg, 34(3), 497-502. 
Chen, N. and Field, E. H. (1995) 'Enhanced type 2 and diminished type 1 cytokines in 
neonatal tolerance', Transplantation, 59(7), 933-41. 
Cimini, M., Boughner, D. R., Ronald, J. A., Johnston, D. E. and Rogers, K. A. (2005) 'Dermal 
fibroblasts cultured on small intestinal submucosa: Conditions for the formation of 
a neotissue', J Biomed Mater Res A, 75(4), 895-906. 
Clyne, A. M. and Edelman, E. R. (2009) 'Vascular growth factor binding kinetics to the 
endothelial cell basement membrane, with a kinetics-based correction for substrate 
binding', Cytotechnology. 
Criado, F. J., Fairman, R. M. and Becker, G. J. (2003) 'Talent LPS AAA stent graft: results of a 
pivotal clinical trial', J Vasc Surg, 37(4), 709-15. 
Davis, N. F., Callanan, A., McGuire, B. B., Flood, H. D. and McGloughlin, T. M. (2011) 
'Evaluation of Viability and Proliferative Activity of Human Urothelial Cells 
Cultured Onto Xenogenic Tissue-Engineered Extracellular Matrices', Urology. 
Davis, N. F., Callanan, A., McGuire, B. B., Mooney, R., Flood, H. D. and McGloughlin, T. M. 
(2011) 'Porcine extracellular matrix scaffolds in reconstructive urology: An ex vivo 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
318 
comparative study of their biomechanical properties', J Mech Behav Biomed Mater, 
4(3), 375-82. 
Davis, N. F., McGuire, B. B., Callanan, A., Flood, H. D. and McGloughlin, T. M. (2010) 
'Xenogenic extracellular matrices as potential biomaterials for interposition grafting 
in urological surgery', J Urol, 184(6), 2246-53. 
Egelhoff, C. J., Budwig, R. S., Elger, D. F., Khraishi, T. A. and Johansen, K. H. (1999) 'Model 
studies of the flow in abdominal aortic aneurysms during resting and exercise 
conditions', J Biomech, 32(12), 1319-29. 
Ferrara, N., Houck, K., Jakeman, L. and Leung, D. W. (1992) 'Molecular and biological 
properties of the vascular endothelial growth factor family of proteins', Endocr Rev, 
13(1), 18-32. 
Freytes, D. O., Badylak, S. F., Webster, T. J., Geddes, L. A. and Rundell, A. E. (2004) 'Biaxial 
strength of multilaminated extracellular matrix scaffolds', Biomaterials, 25(12), 2353-
61. 
Freytes, D. O., Rundell, A. E., Vande Geest, J., Vorp, D. A., Webster, T. J. and Badylak, S. F. 
(2005) 'Analytically derived material properties of multilaminated extracellular 
matrix devices using the ball-burst test', Biomaterials, 26(27), 5518-31. 
Freytes, D. O., Stoner, R. M. and Badylak, S. F. (2008) 'Uniaxial and biaxial properties of 
terminally sterilized porcine urinary bladder matrix scaffolds', J Biomed Mater Res B 
Appl Biomater, 84(2), 408-14. 
Galili, U. (1993) 'Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: 
a major obstacle for xenotransplantation in humans', Immunol Today, 14(10), 480-2. 
Gilbert, T. W., Gilbert, S., Madden, M., Reynolds, S. D. and Badylak, S. F. (2008) 
'Morphologic assessment of extracellular matrix scaffolds for patch tracheoplasty in 
a canine model', Ann Thorac Surg, 86(3), 967-74; discussion 967-74. 
Gilbert, T. W., Sacks, M. S., Grashow, J. S., Woo, S. L., Badylak, S. F. and Chancellor, M. B. 
(2006) 'Fiber kinematics of small intestinal submucosa under biaxial and uniaxial 
stretch', J Biomech Eng, 128(6), 890-8. 
Gilbert, T. W., Stewart-Akers, A. M., Simmons-Byrd, A. and Badylak, S. F. (2007) 
'Degradation and remodeling of small intestinal submucosa in canine Achilles 
tendon repair', J Bone Joint Surg Am, 89(3), 621-30. 
Good, A. H., Cooper, D. K., Malcolm, A. J., Ippolito, R. M., Koren, E., Neethling, F. A., Ye, Y., 
Zuhdi, N. and Lamontagne, L. R. (1992) 'Identification of carbohydrate structures 
that bind human antiporcine antibodies: implications for discordant xenografting 
in humans', Transplant Proc, 24(2), 559-62. 
Gouk, S. S., Lim, T. M., Teoh, S. H. and Sun, W. Q. (2008) 'Alterations of human acellular 
tissue matrix by gamma irradiation: histology, biomechanical property, stability, in 
vitro cell repopulation, and remodeling', J Biomed Mater Res B Appl Biomater, 84(1), 
205-17. 
Greenberg, R. (2003) 'The Zenith AAA endovascular graft for abdominal aortic aneurysms: 
clinical update', Semin Vasc Surg, 16(2), 151-7. 
Greenhalgh, R. M. and Powell, J. T. (2008) 'Registries and RCTs for new interventional 
procedures', Lancet, 372(9642), 891-2. 
Hiles, M. C., Badylak, S. F., Lantz, G. C., Kokini, K., Geddes, L. A. and Morff, R. J. (1995) 
'Mechanical properties of xenogeneic small-intestinal submucosa when used as an 
aortic graft in the dog', J Biomed Mater Res, 29(7), 883-91. 
www.intechopen.com
Tissue-Engineered Extracellular Matrices (ECMs)  
as Adjuvant Scaffolds for Endovascular Aneurysmal Repair (EVAR) 
 
319 
Ho, K. L., Witte, M. N. and Bird, E. T. (2004) '8-ply small intestinal submucosa tension-free 
sling: spectrum of postoperative inflammation', J Urol, 171(1), 268-71. 
Hodde, J., Record, R., Tullius, R. and Badylak, S. (2002) 'Fibronectin peptides mediate 
HMEC adhesion to porcine-derived extracellular matrix', Biomaterials, 23(8), 1841-8. 
Hodde, J. P., Ernst, D. M. and Hiles, M. C. (2005) 'An investigation of the long-term 
bioactivity of endogenous growth factor in OASIS Wound Matrix', J Wound Care, 
14(1), 23-5. 
Kamineni, R. and Heuser, R. R. (2004) 'Abdominal aortic aneurysm: a review of endoluminal 
treatment', J Interv Cardiol, 17(6), 437-45. 
Koren, E., Kujundzic, M., Koscec, M., Neethling, F. A., Richards, S. V., Ye, Y., Zuhdi, N. and 
Cooper, D. K. (1994) 'Cytotoxic effects of human preformed anti-Gal IgG and 
complement on cultured pig cells', Transplant Proc, 26(3), 1336-9. 
Kropp, B. P., Eppley, B. L., Prevel, C. D., Rippy, M. K., Harruff, R. C., Badylak, S. F., Adams, 
M. C., Rink, R. C. and Keating, M. A. (1995) 'Experimental assessment of small 
intestinal submucosa as a bladder wall substitute', Urology, 46(3), 396-400. 
Kropp, B. P., Rippy, M. K., Badylak, S. F., Adams, M. C., Keating, M. A., Rink, R. C. and 
Thor, K. B. (1996a) 'Regenerative urinary bladder augmentation using small 
intestinal submucosa: urodynamic and histopathologic assessment in long-term 
canine bladder augmentations', J Urol, 155(6), 2098-104. 
Kropp, B. P., Sawyer, B. D., Shannon, H. E., Rippy, M. K., Badylak, S. F., Adams, M. C., 
Keating, M. A., Rink, R. C. and Thor, K. B. (1996b) 'Characterization of small 
intestinal submucosa regenerated canine detrusor: assessment of reinnervation, in 
vitro compliance and contractility', J Urol, 156(2 Pt 2), 599-607. 
Lantz, G. C., Badylak, S. F., Coffey, A. C., Geddes, L. A. and Blevins, W. E. (1990) 'Small 
intestinal submucosa as a small-diameter arterial graft in the dog', J Invest Surg, 
3(3), 217-27. 
Laurie, G. W., Horikoshi, S., Killen, P. D., Segui-Real, B. and Yamada, Y. (1989) 'In situ 
hybridization reveals temporal and spatial changes in cellular expression of mRNA 
for a laminin receptor, laminin, and basement membrane (type IV) collagen in the 
developing kidney', J Cell Biol, 109(3), 1351-62. 
Liang, R., Woo, S. L., Takakura, Y., Moon, D. K., Jia, F. and Abramowitch, S. D. (2006) 'Long-
term effects of porcine small intestine submucosa on the healing of medial 
collateral ligament: a functional tissue engineering study', J Orthop Res, 24(4), 811-9. 
Lovekamp, J. J., Simionescu, D. T., Mercuri, J. J., Zubiate, B., Sacks, M. S. and Vyavahare, N. 
R. (2006) 'Stability and function of glycosaminoglycans in porcine bioprosthetic 
heart valves', Biomaterials, 27(8), 1507-18. 
Matsumiya, G., Shirakura, R., Miyagawa, S., Izutani, H., Nakata, S. and Matsuda, H. (1994) 
'Assessment of T-cell subsets involved in antibody production and cell-mediated 
cytotoxicity in rat-to-mouse cardiac xenotransplantation', Transplant Proc, 26(3), 
1214-6. 
McPherson, T. B., Liang, H., Record, R. D. and Badylak, S. F. (2000) 'Galalpha(1,3)Gal 
epitope in porcine small intestinal submucosa', Tissue Eng, 6(3), 233-9. 
Mennander, A., Pimenoff, G., Heikkinen, M., Partio, T., Zeitlin, R. and Salenius, J. P. (2005) 
'Nonoperative approach to endotension', J Vasc Surg, 42(2), 194-9. 
Nakata, M., Pavcnik, D., Uchida, B. T., VanAlstine, W., Timmermans, H. A., Toyota, N., 
Terada, M., Brountzos, E., Kaufman, J. A., Keller, F. S. and Rosch, J. (2003) 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
320 
'Comparison of small intestinal submucosa-covered and noncovered nitinol stents 
with PTFE endografts in injured ovine femoral arteries: a pilot study', Cardiovasc 
Intervent Radiol, 26(5), 459-67. 
Niyyati, M., Petersen, B. D., Pavcnik, D., Uchida, B. T., Timmermans, H. A., Hiraki, T., Wu, 
R. H., Brountzos, E., Keller, F. S. and Rosch, J. (2005) 'A flexible stent with small 
intestinal submucosa covering for direct intrahepatic portocaval shunt: 
experimental pilot study in swine', Cardiovasc Intervent Radiol, 28(2), 215-20. 
Noishiki, Y., Ichikawa, Y., Kosuge, T., Yamazaki, I., Yamamoto, K., Manabe, T., Lu, Y. and 
Yamane, Y. (2001) 'Introduction of tissue engineering concepts into the field of 
endovascular grafts: an attempt to solve endoleakage problems of endovascular 
grafts implanted in aortic aneurysms', Artif Organs, 25(3), 228-35. 
Parodi, J. C., Palmaz, J. C. and Barone, H. D. (1991) 'Transfemoral intraluminal graft 
implantation for abdominal aortic aneurysms', Ann Vasc Surg, 5(6), 491-9. 
Pavcnik, D., Obermiller, J., Uchida, B. T., Van Alstine, W., Edwards, J. M., Landry, G. J., 
Kaufman, J. A., Keller, F. S. and Rosch, J. (2009) 'Angiographic evaluation of carotid 
artery grafting with prefabricated small-diameter, small-intestinal submucosa 
grafts in sheep', Cardiovasc Intervent Radiol, 32(1), 106-13. 
Piterina AV, C. A., Meaney CL, Davis LM, Callanan A, Walsh MT, McGloughlin TM (2009) 
Int J. Mol. Sci 2009 Submitted. 
Raghavan, M. L., Kratzberg, J. A. and Golzarian, J. (2005) 'Introduction to biomechanics 
related to endovascular repair of abdominal aortic aneurysm', Tech Vasc Interv 
Radiol, 8(1), 50-5. 
Record, R. D., Hillegonds, D., Simmons, C., Tullius, R., Rickey, F. A., Elmore, D. and 
Badylak, S. F. (2001) 'In vivo degradation of 14C-labeled small intestinal submucosa 
(SIS) when used for urinary bladder repair', Biomaterials, 22(19), 2653-9. 
Roeder, R., Wolfe, J., Lianakis, N., Hinson, T., Geddes, L. A. and Obermiller, J. (1999) 
'Compliance, elastic modulus, and burst pressure of small-intestine submucosa 
(SIS), small-diameter vascular grafts', J Biomed Mater Res, 47(1), 65-70. 
Roeder, R. A., Lantz, G. C. and Geddes, L. A. (2001) 'Mechanical remodeling of small-
intestine submucosa small-diameter vascular grafts--a preliminary report', Biomed 
Instrum Technol, 35(2), 110-20. 
Rosario, D. J., Reilly, G. C., Ali Salah, E., Glover, M., Bullock, A. J. and Macneil, S. (2008) 
'Decellularization and sterilization of porcine urinary bladder matrix for tissue 
engineering in the lower urinary tract', Regen Med, 3(2), 145-56. 
Sakalihasan, N., Limet, R. and Defawe, O. D. (2005) 'Abdominal aortic aneurysm', Lancet, 
365(9470), 1577-89. 
Sandusky, G. E., Jr., Badylak, S. F., Morff, R. J., Johnson, W. D. and Lantz, G. (1992) 
'Histologic findings after in vivo placement of small intestine submucosal vascular 
grafts and saphenous vein grafts in the carotid artery in dogs', Am J Pathol, 140(2), 
317-24. 
Sarikaya, A., Record, R., Wu, C. C., Tullius, B., Badylak, S. and Ladisch, M. (2002) 
'Antimicrobial activity associated with extracellular matrices', Tissue Eng, 8(1), 63-
71. 
Schoder, M., Pavcnik, D., Uchida, B. T., Corless, C., Timmermans, H. A., Yin, Q., Brountzos, 
E., Nakata, M., Hiraki, T., Niyyati, M., Kaufman, J. A., Keller, F. S. and Rosch, J. 
(2004) 'Small intestinal submucosa aneurysm sac embolization for endoleak 
www.intechopen.com
Tissue-Engineered Extracellular Matrices (ECMs)  
as Adjuvant Scaffolds for Endovascular Aneurysmal Repair (EVAR) 
 
321 
prevention after abdominal aortic aneurysm endografting: a pilot study in sheep', J 
Vasc Interv Radiol, 15(1 Pt 1), 69-83. 
Schussler, O., Shen, M., Shen, L., Carpentier, S. M., Kaveri, S. and Carpentier, A. (2001) 
'Effect of human immunoglobulins on the immunogenicity of porcine 
bioprostheses', Ann Thorac Surg, 71(5 Suppl), S396-400. 
Sellaro, T. L., Ravindra, A. K., Stolz, D. B. and Badylak, S. F. (2007) 'Maintenance of hepatic 
sinusoidal endothelial cell phenotype in vitro using organ-specific extracellular 
matrix scaffolds', Tissue Eng, 13(9), 2301-10. 
Strom, T. B., Roy-Chaudhury, P., Manfro, R., Zheng, X. X., Nickerson, P. W., Wood, K. and 
Bushell, A. (1996) 'The Th1/Th2 paradigm and the allograft response', Curr Opin 
Immunol, 8(5), 688-93. 
Sung, H. J., Su, J., Berglund, J. D., Russ, B. V., Meredith, J. C. and Galis, Z. S. (2005) 'The use 
of temperature-composition combinatorial libraries to study the effects of 
biodegradable polymer blend surfaces on vascular cells', Biomaterials, 26(22), 4557-
67. 
Tabata, Y. (2004) 'Tissue regeneration based on tissue engineering technology', Congenit 
Anom (Kyoto), 44(3), 111-24. 
Tabata, Y. (2005) 'Significance of release technology in tissue engineering', Drug Discov 
Today, 10(23-24), 1639-46. 
Teebken, O. E., Bader, A., Steinhoff, G. and Haverich, A. (2000) 'Tissue engineering of 
vascular grafts: human cell seeding of decellularised porcine matrix', Eur J Vasc 
Endovasc Surg, 19(4), 381-6. 
Thompson, M. M. (2003) 'Controlling the expansion of abdominal aortic aneurysms', Br J 
Surg, 90(8), 897-8. 
Vaught, J. D., Kropp, B. P., Sawyer, B. D., Rippy, M. K., Badylak, S. F., Shannon, H. E. and 
Thor, K. B. (1996) 'Detrusor regeneration in the rat using porcine small intestinal 
submucosal grafts: functional innervation and receptor expression', J Urol, 155(1), 
374-8. 
Veith, F. J., Baum, R. A., Ohki, T., Amor, M., Adiseshiah, M., Blankensteijn, J. D., Buth, J., 
Chuter, T. A., Fairman, R. M., Gilling-Smith, G., Harris, P. L., Hodgson, K. J., 
Hopkinson, B. R., Ivancev, K., Katzen, B. T., Lawrence-Brown, M., Meier, G. H., 
Malina, M., Makaroun, M. S., Parodi, J. C., Richter, G. M., Rubin, G. D., Stelter, W. 
J., White, G. H., White, R. A., Wisselink, W. and Zarins, C. K. (2002) 'Nature and 
significance of endoleaks and endotension: summary of opinions expressed at an 
international conference', J Vasc Surg, 35(5), 1029-35. 
Vorp, D. A. and Vande Geest, J. P. (2005) 'Biomechanical determinants of abdominal aortic 
aneurysm rupture', Arterioscler Thromb Vasc Biol, 25(8), 1558-66. 
Yamada, K., Pavcnik, D., Uchida, B. T., Timmermans, H. A., Corless, C. L., Yin, Q., 
Yamakado, K., Park, J. W., Rosch, J., Keller, F. S., Sato, M. and Yamada, R. (2001) 
'Endoluminal treatment of ruptured abdominal aortic aneurysm with small 
intestinal submucosa sandwich endografts: a pilot study in sheep', Cardiovasc 
Intervent Radiol, 24(2), 99-105. 
Yavuz, K., Geyik, S., Pavcnik, D., Uchida, B. T., Corless, C. L., Hartley, D. E., Goktay, A., 
Correa, L. O., Timmermans, H., Hodde, J. P., Kaufman, J. A., Keller, F. S. and Rosch, 
J. (2006) 'Comparison of the endothelialization of small intestinal submucosa, 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
322 
dacron, and expanded polytetrafluoroethylene suspended in the thoracoabdominal 
aorta in sheep', J Vasc Interv Radiol, 17(5), 873-82. 
Zantop, T., Gilbert, T. W., Yoder, M. C. and Badylak, S. F. (2006) 'Extracellular matrix 
scaffolds are repopulated by bone marrow-derived cells in a mouse model of 
achilles tendon reconstruction', J Orthop Res, 24(6), 1299-309. 
Zarins, C. K., Xu, C. and Glagov, S. (2001) 'Atherosclerotic enlargement of the human 
abdominal aorta', Atherosclerosis, 155(1), 157-64. 
Zhai, Y., Ghobrial, R. M., Busuttil, R. W. and Kupiec-Weglinski, J. W. (1999) 'Th1 and Th2 
cytokines in organ transplantation: paradigm lost?', Crit Rev Immunol, 19(2), 155-72. 
www.intechopen.com
Regenerative Medicine and Tissue Engineering - Cells and
Biomaterials
Edited by Prof. Daniel Eberli
ISBN 978-953-307-663-8
Hard cover, 588 pages
Publisher InTech
Published online 29, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Tissue Engineering may offer new treatment alternatives for organ replacement or repair deteriorated organs.
Among the clinical applications of Tissue Engineering are the production of artificial skin for burn patients,
tissue engineered trachea, cartilage for knee-replacement procedures, urinary bladder replacement, urethra
substitutes and cellular therapies for the treatment of urinary incontinence. The Tissue Engineering approach
has major advantages over traditional organ transplantation and circumvents the problem of organ shortage.
Tissues reconstructed from readily available biopsy material induce only minimal or no immunogenicity when
reimplanted in the patient. This book is aimed at anyone interested in the application of Tissue Engineering in
different organ systems. It offers insights into a wide variety of strategies applying the principles of Tissue
Engineering to tissue and organ regeneration.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Anthony Callanan, Niall F. Davis, Michael T. Walsh and Tim M. McGloughlin (2011). Tissue-Engineered
Extracellular Matrices (ECMs) as Adjuvant Scaffolds for Endovascular Aneurysmal Repair (EVAR),
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials, Prof. Daniel Eberli (Ed.), ISBN: 978-
953-307-663-8, InTech, Available from: http://www.intechopen.com/books/regenerative-medicine-and-tissue-
engineering-cells-and-biomaterials/tissue-engineered-extracellular-matrices-ecms-as-adjuvant-scaffolds-for-
endovascular-aneurysmal-repa
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
